Nucleic Acid Sensing in the Tumor Vasculature

Area of Science:

• Immunology
• Cancer Biology
• Vascular Biology

Background:

• Endothelial cells act as a crucial interface orchestrating immune cell trafficking.
• Tumor endothelial cells actively create an immunosuppressive tumor microenvironment.
• Activating nucleic acid sensors (e.g., cGAS-STING) is a strategy to enhance anti-cancer immune responses.

Purpose of the Study:

• To propose targeting nucleic acid-sensing pathways within tumor vasculature to enhance anti-cancer immunity.
• To review the roles of specific nucleic acid sensors (TREX1 and RIG-I) in the vasculature.
• To provide perspectives on targeting these sensors in combination with antiangiogenic and immune activation therapies.

Main Methods:

• Review of existing literature on endothelial cell function, nucleic acid sensing, and cancer immunotherapy.
• Discussion of the roles of DNA sensor TREX1 and RNA sensor RIG-I in the tumor vasculature.
• Exploration of therapeutic strategies targeting these sensors within the tumor endothelium.

Main Results:

• Tumor endothelial cells possess unique immunosuppressive functions.
• Nucleic acid sensors TREX1 and RIG-I play significant roles in vascular responses within the tumor microenvironment.
• Targeting these sensors offers a novel approach to modulate the tumor vasculature for immune activation.

Conclusions:

• Targeting nucleic acid sensing pathways in tumor vasculature presents a promising strategy to overcome tumor-induced immunosuppression.
• Co-opting vascular and immune cells by targeting endothelial nucleic acid sensors can lead to more effective cancer therapies.
• This approach holds potential for enhancing antiangiogenic and immune activation contexts in cancer treatment.